PROCEPT BioRobotics Corp is a surgical robotics company focused on advancing patient care by developing transformative solutions in urology. The company develops, manufactures, and sells the AquaBeam Robotic System and HYDROS Robotic System, image-guided, surgical robotic systems for use in minimally invasive urologic surgery, with an initial focus on treating benign prostatic hyperplasia, or BPH. Geographically, the company generates a majority of its revenue from the United States and also has a presence in markets outside the U.S.
Last trade$23.90
Day change+$0.355 (+1.51%)
Day range$23.11 – $24.09
Volume552,769
Market cap$1.35B
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$1.35B
Price / earnings
—
Price / book
4.12×
Price / sales
3.84×
EV / sales
3.37×
EV / EBITDA
-10.76×
Profitability
Earnings per share
-$2.00
Return on assets
-24.24%
Return on equity
-34.92%
Dividend yield
0%
Liquidity and leverage
Debt / equity
0.16×
Current ratio
5.89×
Quick ratio
4.73×
Cash ratio
3.1×
Cash flow
Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$85.07M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for PRCT, quarterly periods
Line item
Q3 FY2026 Sep 30, 2026
Q2 FY2026 Jun 30, 2026
Q1 FY2026 Mar 31, 2026
Q4 FY2025 Dec 31, 2025
Q3 FY2025 Sep 30, 2025
Q2 FY2025 Jun 30, 2025
Q1 FY2025 Mar 31, 2025
Q4 FY2024 Dec 31, 2024
Revenue
$98.29M
$94.5M
$83.13M
$76.38M
$83.33M
$79.18M
$69.16M
$68.24M
Cost of revenue
$33.14M
$32.12M
$29.19M
$30.07M
$29.32M
$27.44M
$25M
$24.56M
Gross profit
$65.15M
$62.38M
$53.95M
$46.31M
$54.01M
$51.75M
$44.16M
$43.67M
Selling, general and administrative
$72.51M
$69.67M
$65.09M
$58.3M
$59.01M
$56.3M
$55.2M
$48.32M
Research and development
$20.01M
$20.1M
$21.47M
$19.06M
$18.19M
$17.63M
$16.4M
$15.07M
Total operating expenses
$92.52M
$89.77M
$86.55M
$77.35M
$77.2M
$73.94M
$71.6M
$63.38M
Operating income
-$27.38M
-$27.39M
-$32.61M
-$31.04M
-$23.19M
-$22.19M
-$27.44M
-$19.71M
Interest expense
-$856K
-$842K
-$818K
-$894K
-$919K
-$895K
-$877K
-$969K
Income before taxes
-$26.57M
-$26.77M
-$31.68M
-$29.66M
-$21.38M
-$19.44M
-$24.78M
-$18.49M
Income taxes
-$58K
$94K
-$43K
$190K
$34K
$136K
-$47K
$368K
Net income
-$26.52M
-$26.86M
-$31.64M
-$29.85M
-$21.41M
-$19.58M
-$24.74M
-$18.86M
Net income attributable to common shareholders
-$26.52M
-$26.86M
-$31.64M
-$29.85M
-$21.41M
-$19.58M
-$24.74M
-$18.86M
EBITDA
-$24.84M
-$25.4M
-$30.87M
-$29.33M
-$21.57M
-$20.6M
-$25.96M
-$18.26M
Basic earnings per share
-$0.46
-$0.47
-$0.56
-$0.53
-$0.38
-$0.35
-$0.45
-$0.35
Diluted earnings per share
-$0.46
-$0.47
-$0.56
-$0.53
-$0.38
-$0.35
-$0.45
-$0.35
Recent news
Company coverage with links to the original publishers.
PROCEPT BioRobotics (PRCT) is expected to report Q3 2026 earnings on November 4, with a projected loss of $0.39 per share but revenues up 20.1% year-over-year to $100.07 million. The company has a positive Earnings ESP of +9.79% combined with a Zacks Rank #3 (Hold), suggesting a likely earnings beat. However, the company has only beaten consensus estimates once in the last four quarters.
Grabar Law Office has launched multiple shareholder investigations into four public companies for alleged securities fraud and breach of fiduciary duties. Erasca is accused of making misleading statements about its ERAS-0015 drug candidate and failing to disclose patent infringement risks from Revolution Medicines. Planet Fitness faces allegations of false marketing claims and concealing declining customer acquisition metrics. PROCEPT BioRobotics is investigated for undisclosed discount programs that artificially inflated sales figures and created excess inventory. The Simply Good Foods Company is accused of failing to disclose operational failures and margin erosion related to its OWYN acquisition.
A lawsuit was filed on July 24, 2026, against PROCEPT BioRobotics Corporation alleging the company misrepresented U.S. handpiece unit sales through an undisclosed discount program that incentivized bulk orders beyond actual demand, artificially inflating reported sales and exposing the company to material operational and financial risks.
Grabar Law Office announced investigations into potential breaches of fiduciary duties by officers and directors at Doximity, GoDaddy, Planet Fitness, and PROCEPT BioRobotics. The investigations follow federal securities class action filings alleging misleading statements regarding business metrics, pricing strategies, and financial guidance. Long-term shareholders meeting specific holding periods are eligible to seek corporate reforms and potential compensation at no cost.
A class action lawsuit has been filed against PROCEPT BioRobotics Corporation for allegedly making materially false statements about its business between February 2024 and February 2026. The company allegedly used an undisclosed discount program to artificially inflate handpiece sales, leading to excess inventory of over 10,000 units. Stock price declined significantly following three earnings announcements revealing lower-than-expected sales and inventory issues. Shareholders have until September 22, 2026 to file lead plaintiff motions.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.